Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891838759> ?p ?o ?g. }
Showing items 1 to 52 of
52
with 100 items per page.
- W2891838759 abstract "Background Degeneration of striatal medium-spiny neurons underlies corticostriatal dysfunction in Huntington disease (HD). Inhibition of Phosphodiesterase-10A, an intracellular signaling regulator preferentially expressed in medium-spiny neurons, increases corticostriatal function in preclinical models providing a promising therapeutic target for HD. Aims To assess efficacy on motor function, safety and tolerability of the phosphodiesterase-10A inhibitor PF-02545920 in HD. Methods AMARYLLIS was a double-blind, placebo-controlled, randomized trial (ClinicalTrials.gov, NCT02197130). The primary outcome was the Unified-Huntington’s-Disease-Rating-Scale Total-Motor-Score (UHDRS-TMS). Patients with genetically confirmed symptomatic HD in stages I-II, UHDRS-TMS≥10 and no neuroleptic treatment, were randomized to 5 mg, 20 mg PF-02545920 or placebo twice daily for 26 weeks. Results 216 (79%) of 272 randomized subjects completed AMARYLLIS (5 mg=79, 20 mg=56, placebo=81). UHDRS-TMS and the secondary efficacy assessments UHDRS-Total-Maximum-Chorea score and Clinical-Global-Impression of Improvement showed no benefits compared to placebo. Pre-specified exploratory quantitative motor (Q-Motor) measures showed consistent and dose-dependent improvements. Adverse events were mild or moderate and occurred more frequently at the 20 mg (90%) compared to 5 mg (86%) dose and placebo (72%), most common were somnolence, fatigue, and weight-decrease. Adverse-event-related discontinuations were higher at 20 mg (26%) compared to 5 mg (14%) and placebo (6%). Serious adverse event were not dose-related and Conclusions PF-02545920 was generally safe and sufficiently tolerated. This study did not provide evidence of efficacy in primary or secondary clinical endpoints. But rater-independent improvements in pre-specified Q-Motor measures suggested proof-of-concept for a dose-dependent central effect on motor coordination of unknown clinical significance. Exploration of higher doses possibly in earlier stages of HD may be considered." @default.
- W2891838759 created "2018-09-27" @default.
- W2891838759 creator A5011843432 @default.
- W2891838759 creator A5030072180 @default.
- W2891838759 creator A5031136728 @default.
- W2891838759 creator A5037639447 @default.
- W2891838759 creator A5078546866 @default.
- W2891838759 date "2018-09-01" @default.
- W2891838759 modified "2023-10-17" @default.
- W2891838759 title "J06 A randomized, double-blind, placebo-controlled phase ii efficacy and safety study of the PDE10A inhibitor PF-02545920 in huntington disease (amaryllis)" @default.
- W2891838759 doi "https://doi.org/10.1136/jnnp-2018-ehdn.266" @default.
- W2891838759 hasPublicationYear "2018" @default.
- W2891838759 type Work @default.
- W2891838759 sameAs 2891838759 @default.
- W2891838759 citedByCount "2" @default.
- W2891838759 countsByYear W28918387592021 @default.
- W2891838759 countsByYear W28918387592022 @default.
- W2891838759 crossrefType "proceedings-article" @default.
- W2891838759 hasAuthorship W2891838759A5011843432 @default.
- W2891838759 hasAuthorship W2891838759A5030072180 @default.
- W2891838759 hasAuthorship W2891838759A5031136728 @default.
- W2891838759 hasAuthorship W2891838759A5037639447 @default.
- W2891838759 hasAuthorship W2891838759A5078546866 @default.
- W2891838759 hasConcept C126322002 @default.
- W2891838759 hasConcept C142724271 @default.
- W2891838759 hasConcept C204787440 @default.
- W2891838759 hasConcept C27081682 @default.
- W2891838759 hasConcept C2991744798 @default.
- W2891838759 hasConcept C71924100 @default.
- W2891838759 hasConceptScore W2891838759C126322002 @default.
- W2891838759 hasConceptScore W2891838759C142724271 @default.
- W2891838759 hasConceptScore W2891838759C204787440 @default.
- W2891838759 hasConceptScore W2891838759C27081682 @default.
- W2891838759 hasConceptScore W2891838759C2991744798 @default.
- W2891838759 hasConceptScore W2891838759C71924100 @default.
- W2891838759 hasLocation W28918387591 @default.
- W2891838759 hasOpenAccess W2891838759 @default.
- W2891838759 hasPrimaryLocation W28918387591 @default.
- W2891838759 hasRelatedWork W1533837487 @default.
- W2891838759 hasRelatedWork W2079338632 @default.
- W2891838759 hasRelatedWork W2088083676 @default.
- W2891838759 hasRelatedWork W2290362853 @default.
- W2891838759 hasRelatedWork W2403058484 @default.
- W2891838759 hasRelatedWork W2414115992 @default.
- W2891838759 hasRelatedWork W2468589341 @default.
- W2891838759 hasRelatedWork W2913074078 @default.
- W2891838759 hasRelatedWork W3118611254 @default.
- W2891838759 hasRelatedWork W4233016836 @default.
- W2891838759 isParatext "false" @default.
- W2891838759 isRetracted "false" @default.
- W2891838759 magId "2891838759" @default.
- W2891838759 workType "article" @default.